Effect of Intensive Compared With Standard Glycemia Treatment Strategies on Mortality by Baseline Subgroup Characteristics
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 27 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine if baseline subgroups in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial can be identified for whom intensive compared with standard glycemia treatment had different effects on all-cause mortality. RESEARCH DESIGN AND METHODS: Exploratory post hoc intention-to-treat comparisons were made between intensive and standard glycemia groups on all-cause mortality by subgroups defined by baseline characteristics. RESULTS: There were few significant interactions between baseline characteristics and effects of intensive versus standard glycemia treatment on mortality: self-reported history of neuropathy (hazard ratio [HR] 1.95, 95% CI 1.41–2.69) versus no history of neuropathy (0.99, 0.79–1.26; P value for interaction 0.0008), higher A1C (A1C >8.5%: HR 1.64, 95% CI 1.22–2.22; A1C 7.5–8.4%: 1.00, 0.75–1.34; A1C <7.5%: 1.00, 0.67–1.50; P value for interaction 0.04), and aspirin use (HR 1.45, 95% CI 1.13–1.85, compared with 0.96, 0.72–1.27, in nonusers; P value for interaction 0.03). CONCLUSIONS: We found a remarkable similarity of effect from intensive compared with standard glycemia treatment on mortality across most baseline subgroups. No differential effect was found in subgroups defined by variables anticipated to have an interaction: age, duration of diabetes, and previous history of cardiovascular disease. The three baseline characteristics that defined subgroups for which there was a differential effect on mortality may help identify patients with type 2 diabetes at higher risk of mortality from intensive regimens for glycemic control. Further research is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · cited 1×
“Adding to the controversy were results of the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and Veterans Affairs Diabetes Trial (VADT), demonstrating that although there was no significant reduction in the primary end point of CVD events, there was no increase in mo…”
ResultHaffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“Adding to the controversy were results of the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and Veterans Affairs Diabetes Trial (VADT), demonstrating that although there was no significant reduction in the primary end point of CVD events, there was no increase in mo…”
ResultStandards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445 · cited 1×
“Analyses were conducted using intention-to-treat comparisons between the intensive glycemia and standard groups on the mortality rate within each subgroup as defined in Table 1 above (15).”
MethodFeldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1281 · Cited by 1,293 · cited 1×
“Complete details of the study design and conduct have been previously published (13,14).”
Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., Lee, R., Bancroft, J., MacEwan, S., Shepherd, J., et al. (2008) · BMJ · doi:10.1136/bmj.a1840 · Cited by 977
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
Young, L. H., Wackers, F. J. T., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Heller, G. V., Iskandrian, A. E., Wittlin, S. D., Filipchuk, N., et al. (2009) · JAMA · doi:10.1001/jama.2009.476 · Cited by 809
Cited by
Items 101–160 of 160
Is there a connection between postprandial hyperglycemia and IGT related sensory nerve dysfunction?
Németh, N., Putz, Z., Istenes, I., Körei, A. E., Vági, O. E., Kempler, M., Gandhi, R. A., Jermendy, G., Tesfaye, S. H., Tabák, Á. G., et al. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.05.001 · Cited by 10
Alam, U., Ponirakis, G., Asghar, O., Petropoulos, I. N., Azmi, S., Jeziorska, M., Marshall, A. G., Boulton, A. J. M., Efron, N., & Malik, R. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082249 · Cited by 10
“It is also one of only three independent risk factors for increased mortality in patients with Type 2 diabetes mellitus (T2DM) undergoing more intensive glycemic control [3].”
BackgroundAssessment of cardiac autonomic neuropathy in long standing type 2 diabetic women
Refaie, W. (2013) · The Egyptian Heart Journal · doi:10.1016/j.ehj.2013.06.002 · Cited by 10
Genetic Factors Associated with the Development of Neuropathy in Type 2 Diabetes
Tordai, D. Z., Hajdú, N., Rácz, R., Istenes, I., Békeffy, M. Z., Vági, O. E., Kempler, M., Körei, A. E., Tóbiás, B., Illés, A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031815 · Cited by 11
van der Leeuw, J., Visseren, F. L. J., Woodward, M., van der Graaf, Y., Grobbee, D. E., Harrap, S. B., Heller, S. R., Mancia, G., Marre, M., Poulter, N. R., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-4082-5 · Cited by 8
“The interaction of intensive treatment with HbA1c level on risk of death, as reported in a post hoc analysis of the ACCORD trial, was not significant in this study [34].”
Singleton, M. J., Soliman, E. Z., Bertoni, A. G., Whalen, S. P., Bhave, P. D., & Yeboah, J. (2020) · Diabetes · doi:10.2337/db20-0401 · Cited by 10
“5), and regular aspirin use (41), we performed a supplementary analysis in which we assessed for interaction between these participant characteristics and baseline prolonged QT with regard to the outcome of mortality.”
MethodSam, S., Pekmezaris, R., Nouryan, C. N., Tan, R., Conrardy, A., Ward, M. F., Schwalberg, A., Vij, B., Silverman, H., Guzik, H. J., et al. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03680.x · Cited by 8
Reevaluating Goals of Insulin Therapy: Perspectives from Large Clinical Trials
Riddle, M. C., & Yuen, K. C. J. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.003 · Cited by 7
Diabetes and Long-Term Complications
Cagliero, E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00051-2 · Cited by 11
Glycemia and cardiovascular risk: challenging evidence based medicine.
Kitsios, K., Τσάπας, Α., & Karagianni, P. (2011) · PubMed · Cited by 10
Aron, D. C. (2013) · The Joint Commission Journal on Quality and Patient Safety · doi:10.1016/s1553-7250(13)39015-1 · Cited by 8
Intensive Glycemic Therapy in Type 2 Diabetes Patients With Cardiac Autonomic Dysfunction
Huang, Y., Xie, P., Zhang, S., Liu, M., Huang, R., Xiong, Z., Zhong, X., Lin, Y., Zhou, Z., Zhang, W., et al. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.03.020 · Cited by 6
Glucose Control and Cardiovascular Outcomes in Individuals with Diabetes Mellitus
Avitabile, N. A., Banka, A., & Fonseca, V. A. (2012) · Heart Failure Clinics · doi:10.1016/j.hfc.2012.06.009 · Cited by 8
Self-citationBloomgarden, Z. T., EINHORN, D. F., Handelsman, Y., Misra, A., Zonszein, J., Grunberger, G., Jellinger, P. S., & Garber, A. J. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12668 · Cited by 6
What have clinical trials taught us about brain health?
Lee, K., & Bae, H. (2023) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2023.100199 · Cited by 7
“The ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial was designed to ascertain if intensive management of hyperglycemia, blood pressure, or lipid levels could curtail cardiovascular events or mortality relative to conventional care [27].”
BackgroundPhysical activity in diabetes: Is any better than none?
Carson, A. P., Williams, L. B., & Hill, A. N. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.10.012 · Cited by 5
“…used this cut-point in their analyses, but this approach may obscure possible differential effects of PA across the spectrum of glycemic control (Calles-Escandon et al., 2010; Desouza, Bolli, & Fonseca, 2010), particularly for individuals with glycemic levels that are furthest from the…”
BackgroundEffects of insulin on peripheral nerves
Stecker, M. M., & Stevenson, M. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.03.009 · Cited by 5
“A similar issue applies to many clinical studies such as the Diabetes Control and Complications Trial (DCCT) (Anonymous, 1995) and ACCORD (Calles-Escandon et al., 2010; Pop-Busui et al., 2010; Vinik, Maser, & Ziegler, 2010) studies since it is difficult to separate effects of insulin from the…”
MethodCardiac Autonomic Neuropathy in Diabetes Mellitus Patients – Are We Aware of the Consequences?
Moțățăianu, A., Bărcuţean, L., Maier, S., Bălașa, A. F., & Stoian, A. (2020) · Acta Marisiensis. Seria Medica · doi:10.2478/amma-2020-0003 · Cited by 5
“The existence of CAN doubled the risk of mortality and the association between autonomic and somatic nervous impairment increases the risk of cardiovascular mortality by almost three-fold [15, 60].”
BackgroundYeh, H., Huang, E. S., LEVIN, P. A., Liu, S., & Brancati, F. L. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03681.x · Cited by 5
“Moreover, in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, all-cause mortality in the intensive and standard glycemia groups was not different in participants aged 65 and older.(5) A higher glycemic goal may be appropriate for older adults, particularly those with severe or frequent hypoglycemi…”
BackgroundKloecker, D. E., Davies, M. J., Pitocco, D., Khunti, K., & Zaccardi, F. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3634 · Cited by 4
Quality of life in diabetes mellitus assessed on the basis of Hungarostudy Health Panel survey
Sal, I., Susánszky, É., & Papp, I. (2013) · Orvosi Hetilap · doi:10.1556/oh.2013.29579 · Cited by 4
Cardiovascular Disease and Glycemic Treatment
Bloomgarden, Z. T. (2010) · Diabetes Care · doi:10.2337/dc10-zb11 · Cited by 4
“5% had greater mortality (19), and every 1% lower A1C was associated with more than a 50% reduction in mortality, so that an in-study A1C above 7% was associated with higher mortality (20).”
BackgroundHeng, X.-P., Yang, L., Chen, M., Li, L., Huang, S.-P., & Lei, Y. (2015) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-015-0780-5 · Cited by 4
Influence of Diabetes and Hemodialysis against Nerve Conduction Studies
Kato, Y., Bando, H., Fujikawa, T., Narutaki, M., Yamamoto, M., Kakutani, H., Shirai, Y., Ishikura, K., Kusunoki, K., Tanaka, S., et al. (2017) · Journal of General Practice · doi:10.4172/2329-9126.1000343 · Cited by 3
“The relationship between the presence of neuropathy were assessed by NCS and future mortality in diabetic patients [27,28].”
MethodWang, Y., Zhang, J., Ma, Y., Song, X., Li, S., Zhan, X., & Wu, L. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0863-9 · Cited by 3
Bălașa, R., Bajkó, Z., Maier, S., Voidăzan, S. T., & Moțățăianu, A. (2015) · Acta Marisiensis. Seria Medica · doi:10.1515/amma-2015-0015 · Cited by 3
“The results from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study demonstrated at a level of medicine-based evidence that cardiac autonomic dysfunction and neuropathy are powerful predictors of risk of mortality, and that patients with cardiac and somatic neuropathy represent a high-risk group in w…”
ResultObjectifs du contrôle de la glycémie
Imran, S. A., RABASA-LHORET, R. P. R., & Ross, S. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.036 · Cited by 4
Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
Schinner, S. (2011) · Yearbook of Medicine · doi:10.1016/s0084-3873(11)00369-5 · Cited by 3
Диабетическая кардиомиопатия: лечение
Serhiyenko, A. A., & Serhiyenko, V. A. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.16.8.2020.222888 · Cited by 3
The Avandia debate: An unhappy conclusion
Bloomgarden, Z. T., & Handelsman, Y. (2010) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00096.x · Cited by 3
Is glycemic control a quinidine‐like intervention? 控制血糖与使用奎尼丁治疗一样吗?
Bloomgarden, Z. T. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12170 · Cited by 3
Controlling glucose levels in elderly people—benefits versus risks
Riddle, M. C. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.23 · Cited by 2
Núñez, J. E., Bonanad, C., Navarro, J. P., Bondanza, L., Artero, A., Ventura, S., Núñez, E., Miñana, G., Sanchís, J. M., & Fernández‐Real, J. M. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.10.019 · Cited by 2
Rationale for glycemic control to improve cardiovascular outcome: Lessons from east and west
Bloomgarden, Z. T., & Chan, J. C. N. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13204 · Cited by 2
Drăgoi, I. I., Popescu, F. G., Bowling, F. L., Bondor, C. I., & Ionac, M. E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206516 · Cited by 2
Sankaranarayanan, A., & Malik, R. A. (2015) · Early Intervention in Psychiatry · doi:10.1111/eip.12258 · Cited by 2
WITHDRAWN: Targets for Glycemic Control
Imran, S. A., RABASA-LHORET, R. P. R., & Ross, S. A. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.04.008 · Cited by 4
RetractedDifferential Diagnosis of Abnormal Symptoms and Signs
Ettinger, A. B., & Weisbrot, D. M. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139028899.003 · Cited by 1
Making sense of outcomes in the ACCORD trial
White, A., & Fisher, M. (2011) · Practical Diabetes · doi:10.1002/pdi.1567 · Cited by 1
Núñez, J. E., Bonanad, C., Navarro, J. P., Bondanza, L., Artero, A., Ventura, S., Núñez, E., Miñana, G., Sanchís, J. M., & Fernández‐Real, J. M. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.10.019 · Cited by 1
Joy, S. V., Freeman, J. S., & LaSalle, J. R. (2011) · Osteopathic Family Physician · doi:10.1016/j.osfp.2011.07.002 · Cited by 1
Medical Specialties’ View of Autonomic System Measurements
Colombo, J., Arora, R. R., DePace, N. L., & Vinik, A. I. (2014) · Springer eBooks · doi:10.1007/978-3-319-07371-2_11 · Cited by 1
CALPASTATIN OVER-EXPRESSION REDUCES CARDIAC FIBROSIS IN A MURINE MODEL OF TYPE 2 DIABETES
Singh, M. K. (2011) · Scholarship@Western (Western University) · Cited by 1
Type 2 Diabetes: General Introduction
Levy, D. (2011) · Wiley eBooks · doi:10.1002/9781444391152.ch5 · Cited by 1
Autonomic Dysfunction Versus Neuropathy
Colombo, J., Arora, R. R., DePace, N. L., & Vinik, A. I. (2014) · Springer eBooks · doi:10.1007/978-3-319-07371-2_13
Colombo, J., Arora, R. R., DePace, N. L., & Vinik, A. I. (2014) · Springer eBooks · doi:10.1007/978-3-319-07371-2_14
Summary: General Applications of Parasympathetic and Sympathetic Monitoring
Colombo, J., Arora, R. R., DePace, N. L., & Vinik, A. I. (2014) · Springer eBooks · doi:10.1007/978-3-319-07371-2_32
Autonomic failure or syndromes
Singh, R., & Colombo, J. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139028899.012
Screening and assessment of cardiac autonomic neuropathy in long-standing type 2 diabetic women
Refaie, W. (2013) · The Egyptian Journal of Internal Medicine · doi:10.7123/01.ejim.0000428127.78926.14
Diabetic neuropathy in the elderly
Cherdak, M. A., & Mkhitaryan, E. A. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-11-53-62
de Vries, T. I. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/352
Conget, I., Aronson, R., Lee, S., Cohen, O., & Reznik, Y. (2014) · Diabetes Care · doi:10.2337/dc14-1632 · Cited by 1
“This represents an additional therapeutic opportunity to address the unmet challenge of treating patients who are failing MDI and have a high-risk profile similar to participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial (3,4).”
Background(2011) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283457c7d
Current literature in diabetes
(2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1027
Diabetic autonomic neuropathy, measurement and management; part II: management
Colombo, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820669-0.00020-7
Colombo, J., Arora, R. R., DePace, N. L., & Vinik, A. I. (2014) · Springer eBooks · doi:10.1007/978-3-319-07371-2_21
Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
Schinner, S. (2011) · Yearbook of Endocrinology · doi:10.1016/j.yend.2011.06.008
Azmi, S., Alam, U., & Malik, R. A. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch45 · Cited by 1
A Study on Autonomic Dysfunction in Type 2 Diabetes Mellitus with Peripheral Neuropathy
Kuriakose, S., Singhal, A., Bansal, N., Shukla, R., Paul, S. M., & Singhal, A. (2024) · Journal of Marine Medical Society · doi:10.4103/jmms.jmms_6_24
Lim, L., Foo, S. H., Ghani, R. A., Ibrahim, L., Wahab, N. A., Mohamed, W. M. I. W., Lim, S.-C., Mustafa, N., Hew, F., Hussein, Z. B., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01927-8
Metadata
- Authors
- Calles-Escandón, J., Lovato, L. C., Simons-Morton, D. G., Kendall, D. M., Pop-Busui, R., Cohen, R. M., Bonds, D. E., Fonseca, V. A., Ismail-Beigi, F., Banerji, M. A., Failor, A., & Hamilton, B.
- Affiliations
- Wake Forest University Health Sciences (US)
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland;
- Park Nicollet Health Services (US)
- Department of Endocrinology, Metabolism, and Nutrition, University of Michigan Medical School, Ann Arbor, Michigan;
- University of Cincinnati Medical Center (US)
- National Institutes of Health (US)
- Tulane University (US)
- VA Medical Center, Section of Endocrinology, University of Cleveland, Cleveland, Ohio;
- State University of New York (US)
- University of Washington (US)
- University of Maryland, Baltimore (US)
- Corresponding author
- Calles-Escandón, Jorge
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-01-26
- Volume
- 33
- Issue
- 4
- Pages
- 721-727
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2845012
- OpenAlex
- W2136749671
- Cited by
- 160
- References
- 28
- Citations by year
- 2026: 1 · 2024: 5 · 2023: 6 · 2022: 3 · 2021: 6 · 2020: 13 · 2019: 3 · 2018: 7 · 2017: 5 · 2016: 14 · 2015: 20 · 2014: 22 · 2013: 13 · 2012: 10
- FWCI
- 13.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- tight glycemic control, type 2 diabetes, all-cause mortality, subgroup analysis, HbA1c, aspirin use, cardiovascular risk, ACCORD trial, treatment effect heterogeneity
- MeSH terms
- Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.